Dermatology

Roflumilast is approved as a once daily and steroid-free cream for rapid disease clearance and significant reduction in itch and for long-term disease control.

When initiated at a 15 mg dose and escalated to 30 mg, upadacitinib showed superiority compared with dupilumab, achieving Eczema Area and Severity Score (EASI) 90 at week 16.

Hyperhidrosis affects an estimated 10 million individuals in the US and is characterized by abnormally increased sweating, beyond what is necessary to regulate body temperature.

The autoinjector will provide another option for adults in addition to the prefilled syringe that is currently available.

Reducing sodium intake is associated with decreased risk of atopic dermatitis (AD) and flares.

Parents and caregivers sometimes have concerns about their children receiving these injections, but researchers and experts assure that the FDA-approved biologic is safe and effective in young populations.

At the ASHP Pharmacy Futures 2024 conference, Scott D. Nelson, PharmD, MS, ACHIP, FAMIA, discusses research showed that although AI models can significantly enhance diagnostic accuracy, they can also exacerbate existing disparities.

The new approval increases the previous dosing for surface area treatment from 25 cm2 to up to 100 cm2.

Although sun-protective measures have been increasing, the incidence of skin cancer has also increased, suggesting better targeted interventions and patient education are needed.

Corticophobia is defined as a phobia of topical corticosteroids due to negative feelings or beliefs, which can come from misinformation about the long-term effects.

The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.

Sharing data and a personal recommendation can make a difference in a patient’s life

Bimekizumab-bkzx (Bimzelx; Union Chimique Belge) is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin (IL)-17A and IL-17F.

It is unclear why the vaccines were less effective in women, but researchers note that the findings can be important when determining immune therapy outcomes in patients with melanoma.

The efficacy data are consistent with other phase 3 studies, reinforcing lebrikizumab's potential as a first-line treatment across a range of skin tones.

To date, this is the only targeted therapy indicated for the treatment of generalized pustular psoriasis.

The agency will focus on collaboration to protect public health; advancing regulatory approaches; developing standards, guidelines, and best practices; and supporting research that evaluates and monitors AI performance.

Compared to placebo, risankizumab significantly reduced symptom severity for patients with moderate to severe disease.

The drug is indicated for patients 5 years of age and older with progressive familial intrahepatic cholestasis and cholestatic pruritus in pediatric patients with Alagille syndrome.

The tool consolidates and highlights key features that would be considered when choosing a biosimilar adalimumab.

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

This treatment improved the severity of symptoms in patients with scalp and nail psoriasis.

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.

Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

Topical niacinamide stabilizes the skin's outer barrier, reducing water loss and improving moisture levels in the epidermis.

With a wide array of OTC products, pharmacists can help patients select the right regimen

Treating older patients requires a greater focus on treating their AD without exacerbating their comorbidities.